ライフサイエンスコーパス: myelomonocytic

1 IFP expression was sufficient to induce a myelomonocytic AML even when expressed in wild type bone

2 giogenesis involves both bone marrow-derived myelomonocytic and endothelial progenitor cells as well

3 nd with their ability to give rise to mature myelomonocytic and lymphoid cells.

4 rminal kinase signaling pathways, leading to myelomonocytic and monocytic AML cell differentiation.

5 We report that a subset of malignant myelomonocytic and monocytic AML cells (French-American-

6 n leukemia and have therapeutic potential in myelomonocytic and monocytic AMLs.

7 ith impaired mobilization of endothelial and myelomonocytic angiogenic progenitors from the bone marr

8 When recalibrated for myelomonocytic blast enumeration, this approach is super

9 TCL1 was also expressed in myelomonocytic blasts of 3 transformed BT cases but not

10 al precursor cells and "vascular modulatory" myelomonocytic (CD11b+) cells.

11 signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T ce

12 the myeloid compartment that evoked a clonal myelomonocytic cell expansion, splenomegaly, multi-organ

13 Basic research into human mature myelomonocytic cell function, myeloid lineage diversific

14 Moreover, when tested in a porcine myelomonocytic cell line, NSP1beta inhibited Sendai viru

15 Using the THP-1 myelomonocytic cell line, we demonstrated for the first

16 Human myelomonocytic cell lines accurately model PLD-dependent

17 Using chick HD-11 and human THP-1 myelomonocytic cell lines, we have shown that macrophage

18 ement to direct activity of reporter gene in myelomonocytic cell lines.

19 onocytic leukemia (JMML) is characterized by myelomonocytic cell overproduction and commonly bears ac

20 results in a hyperproliferative response of myelomonocytic cell populations to growth factor stimula

21 and highlight Ccr2 as the primary driver of myelomonocytic cell recruitment in acutely inflamed cont

22 eam to salivary glands and is dependent on a myelomonocytic cell type other than mature macrophages.

23 ) ASCs in the medullary cords migrated along myelomonocytic cells and arrested in contact with them.

24 Thus, circulating and lung myelomonocytic cells and endothelial cells are a major s

25 mistry of lung autopsy samples revealed that myelomonocytic cells and endothelial cells express high

26 However, PR expression in U937 myelomonocytic cells and primary murine myeloid bone mar

27 Peripheral blood myelomonocytic cells are important for cytomegalovirus d

28 The role of inflammatory myelomonocytic cells as mediators of these processes and

29 ne expression in monocytes, macrophages, and myelomonocytic cells as well as in epidermal keratinocyt

30 e and found EYFP gene expression not only in myelomonocytic cells but also in a fraction of HSCs as w

31 y described a mouse line that contains green myelomonocytic cells due to the knock-in of enhanced gre

32 dissect the branching between erythroid and myelomonocytic cells during in vitro differentiation of

33 grade Abeta(1-42), and ACE overexpression in myelomonocytic cells enhances their immune function.

34 Macrophages, THP-1 cells, and other human myelomonocytic cells expressed both PLD1 and PLD2 protei

35 o generate large numbers of patient-specific myelomonocytic cells for in vitro studies of human disea

36 porting this hypothesis, Siglec-9-expressing myelomonocytic cells found in human tumor samples were a

37 a similar protocol could be used to generate myelomonocytic cells from induced pluripotent stem cells

38 inct roles that reflect the dual function of myelomonocytic cells in cancer progression.

39 ses monoblastic leukemia and transforms only myelomonocytic cells in culture.

40 tions, spanning progenitor to mature myeloid/myelomonocytic cells in normal bone marrows with further

41 erm repopulating cells give rise to expanded myelomonocytic cells in vivo.

42 Myelomonocytic cells play a key role in the progression

43 The overexpression of ACE and iNOS by myelomonocytic cells substantially boosts innate immunit

44 sults provide direct evidence that committed myelomonocytic cells such as macrophages can produce fun

45 However, myelomonocytic cells such as neutrophils have also been

46 iocytes (FLS) cell lines that were bereft of myelomonocytic cells to examine whether mesenchymal-deri

47 nctional analyses revealed that hESC-derived myelomonocytic cells were comparable to their correspond

48 omposed of myeloperoxidase-positive immature myelomonocytic cells with histiocytoid morphology.

49 to ILT4 leads to a tolerogenic phenotype of myelomonocytic cells with lower surface expression of de

50 cognition by innate MHC class I receptors on myelomonocytic cells, and functional impairment of DCs,

51 on maternal uterine natural killer (NK) and myelomonocytic cells, CD94/NKG2, leukocyte immunoglobuli

52 Among DC-HIL(+) myelomonocytic cells, during growth of implanted mouse m

53 oliferation, differentiation and function of myelomonocytic cells, including osteoclasts.

54 ifferentiation in certain cell types, namely myelomonocytic cells, osteoblasts, skeletal muscle cells

55 lineage, they do not include mature CD11b(+) myelomonocytic cells, such as macrophages.

56 ermore, GATA-1 induced apoptosis of proB and myelomonocytic cells, which could not be prevented by en

57 re also detected in transduced human PLB-985 myelomonocytic cells.

58 characterized by excessive proliferation of myelomonocytic cells.

59 tiple chemoattractants capable of recruiting myelomonocytic cells.

60 mechanisms and rely instead on CTL-recruited myelomonocytic cells.

61 y MHC class I-specific receptor expressed on myelomonocytic cells.

62 opment and in the maturation and function of myelomonocytic cells.

63 low amounts of BAFF mRNA relative to that of myelomonocytic cells.

64 epatocytes are primarily derived from mature myelomonocytic cells.

65 eversed by transgenic Siglec-9 expression in myelomonocytic cells.

66 Endothelial progenitor cells (EPCs) and myelomonocytic circulating angiogenic cells (CACs) are c

67 a reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.

68 and C/EBPalpha (Cebpa) have general roles in myelomonocytic development, but the transcriptional basi

69 l antibody directed against the cell surface myelomonocytic differentiation antigen CD33.

70 tion exhibiting increased cell cycling and a myelomonocytic differentiation bias.

71 c cells rescued the PU.1 knockdown-initiated myelomonocytic differentiation block.

72 lso been described, but a role for TIMP-1 in myelomonocytic differentiation has not been previously r

73 ology, and exhibited increased expression of myelomonocytic differentiation markers, including CD11b,

74 action of pro-T cells possess plasticity for myelomonocytic differentiation that can be activated by

75 ogenitors expressing activating Shp2 undergo myelomonocytic differentiation, despite being subjected

76 uration arrest at an identical late stage of myelomonocytic differentiation, putatively a monopotent

77 rylation, expression of RIG-E and RIG-G, and myelomonocytic differentiation-specific down-regulation

78 nitors preserves CD34 expression and impairs myelomonocytic differentiation.

79 MafB is a transcription factor that induces myelomonocytic differentiation.

80 nced immune response, coupled with increased myelomonocytic expression of catalytically active ACE, p

81 ltipotential progenitor cell maintenance and myelomonocytic fate and suggests Glut1 as potential drug

82 ts EPO-stimulated HSCs to differentiate into myelomonocytic fates, altering in vivo HSC responses and

83 le attractors corresponding to erythroid and myelomonocytic fates, as well as an uncommitted metastab

84 ch regulate the choice between erythroid and myelomonocytic fates.

85 ere mainly mediated by interactions with the myelomonocytic HLA class I receptor leukocyte immunoglob

86 -N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic hyperplasia and progressed to fatal myelo

87 MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemia

88 of developing leukaemia, especially juvenile myelomonocytic leukaemia (JMML), a childhood myeloprolif

89 ere applied to BALB/c mice with transplanted myelomonocytic leukaemia (WEHI-3) and Human promyelocyti

90 astic syndromes or non-proliferative chronic myelomonocytic leukaemia (white blood cell count <13 000

91 blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia based on local site assessment,

92 ed after myelodysplastic syndrome or chronic myelomonocytic leukaemia); and relapsed or refractory AM

93 in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative

94 with blast-phase disease), one with chronic myelomonocytic leukaemia, and seven with myelofibrosis.

95 eukaemia, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, myelodysplastic syndrome, or m

96 h-risk myelodysplastic syndromes, or chronic myelomonocytic leukaemia.

97 er with myelodysplastic syndromes or chronic myelomonocytic leukaemia.

98 enes for polycystic kidney disease and acute myelomonocytic leukaemia.

99 s study, we address this question in chronic myelomonocytic leukaemia.

100 agnosed myelodysplastic syndromes or chronic myelomonocytic leukaemia; 43 of the enrolled patients we

101 ximately 75% incidence) and SRSF2 in chronic myelomonocytic leukemia ( approximately 28% incidence).

102 ed patients with higher-risk MDS and chronic myelomonocytic leukemia (CMML) 1:1:1 to azacitidine (75

103 Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocyt

104 s of myeloid malignancies resembling chronic myelomonocytic leukemia (CMML) and myelodysplastic syndr

105 B fusion oncogene is associated with chronic myelomonocytic leukemia (CMML) and results in the expres

106 ations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML

107 Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by muta

108 myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases.

109 Exome sequencing studies in chronic myelomonocytic leukemia (CMML) illustrate a mutational l

110 mouse model resemble those of human chronic myelomonocytic leukemia (CMML) in its transformation to

111 Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic

112 Chronic myelomonocytic leukemia (CMML) is a hematologic malignan

113 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic synd

114 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myel

115 The natural course of chronic myelomonocytic leukemia (CMML) is highly variable but a

116 Here, we showed that chronic myelomonocytic leukemia (CMML) patients with ASXL1 mutat

117 myeloid leukemia (AML) patients, 32 chronic myelomonocytic leukemia (CMML) patients, and 96 healthy

118 us pathogenesis to those observed in chronic myelomonocytic leukemia (CMML) patients.

119 The diagnosis of chronic myelomonocytic leukemia (CMML) remains centered on morph

120 Human ASXL1 is mutated frequently in chronic myelomonocytic leukemia (CMML) so an ASXL/BAP1 complex m

121 k myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) were randomized 1:1 to re

122 Adults with advanced MDS or chronic myelomonocytic leukemia (CMML) were randomized to 1 of 3

123 omic DNA from 245 patients--119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hy

124 oring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some

125 Chronic myelomonocytic leukemia (CMML), a myelodysplastic/myelop

126 myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukem

127 (CLL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endom

128 e myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML), including identical soma

129 tion, with a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was serially trans

130 ras G12D/+ bone marrow cells develop chronic myelomonocytic leukemia (CMML), while approximately 8% o

131 ng the myeloproliferative variant of chronic myelomonocytic leukemia (CMML), with a prolonged latency

132 NRAS rapidly and efficiently induced chronic myelomonocytic leukemia (CMML)- or acute myeloid leukemi

133 y shown in the related human disease chronic myelomonocytic leukemia (CMML).

134 MPN that accurately models JMML and chronic myelomonocytic leukemia (CMML).

135 n of SRSF2 (Pro95) in 275 cases with chronic myelomonocytic leukemia (CMML).

136 iferative neoplasm, similar to human chronic myelomonocytic leukemia (CMML).

137 clonal malignancy closely resembling chronic myelomonocytic leukemia (CMML).

138 cogenes in a subset of patients with chronic myelomonocytic leukemia (CMML).

139 myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

140 T2-WT) and mutant (TET2-MT) cases of chronic myelomonocytic leukemia (CMML).

141 ent in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogen

142 yeloid malignancies, particularly in chronic myelomonocytic leukemia (CMML; 48%) and MDS/MPD-unclassi

143 lts with MDS/MPN subtypes, including chronic myelomonocytic leukemia (CMML; n = 119), atypical chroni

144 y members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemi

145 features that overlap with those of juvenile myelomonocytic leukemia (JMML) and chronic myelomonocyti

146 acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMML) and LEOPARD syndrome freq

147 hildren with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irradiated m

148 matopoietic malignancies, including juvenile myelomonocytic leukemia (JMML) and T-cell lymphoblastic

149 ctive RAS signaling is prevalent in juvenile myelomonocytic leukemia (JMML) and the myeloproliferativ

150 myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndr

151 ) hypersensitivity is a hallmark of juvenile myelomonocytic leukemia (JMML) but has not been systemat

152 ndividuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations i

153 Juvenile myelomonocytic leukemia (JMML) is a lethal disease of yo

154 Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative d

155 Juvenile myelomonocytic leukemia (JMML) is a pediatric myeloproli

156 Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive

157 Juvenile myelomonocytic leukemia (JMML) is a rare clonal myelopro

158 Juvenile myelomonocytic leukemia (JMML) is a rare pediatric myelo

159 Juvenile myelomonocytic leukemia (JMML) is a typically aggressive

160 Juvenile myelomonocytic leukemia (JMML) is a unique clonal hemato

161 Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive h

162 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

163 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

164 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

165 Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatri

166 Juvenile myelomonocytic leukemia (JMML) is characterized by hyper

167 Juvenile myelomonocytic leukemia (JMML) is characterized by myelo

168 Thirdly, using a juvenile myelomonocytic leukemia (JMML) patient-specific assay we

169 myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fash

170 ting the molecular underpinnings of juvenile myelomonocytic leukemia (JMML) with the generation of in

171 own to underlie the pathogenesis of juvenile myelomonocytic leukemia (JMML), a fatal childhood diseas

172 s individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferati

173 PTPN11 (SHP-2) are associated with juvenile myelomonocytic leukemia (JMML), a myeloproliferative dis

174 sis type 1 (NF1) are predisposed to juvenile myelomonocytic leukemia (JMML), an aggressive myeloproli

175 al investigate the pathogenesis of juvenile myelomonocytic leukemia (JMML), demonstrating that mutan

176 ood acute leukemias, in addition to juvenile myelomonocytic leukemia (JMML), which is a myeloprolifer

177 L, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML).

178 associated with an elevated risk of juvenile myelomonocytic leukemia (JMML).

179 patients with de novo, nonsyndromic juvenile myelomonocytic leukemia (JMML).

180 of hematologic disorders, including juvenile myelomonocytic leukemia (JMML).

181 (ras), is frequently inactivated in juvenile myelomonocytic leukemia (JMML).

182 ferative disorders (MPD), including juvenile myelomonocytic leukemia (JMML).

183 nd the myeloproliferative variant of chronic myelomonocytic leukemia (JMML/MP-CMML).

184 nd the myeloproliferative variant of chronic myelomonocytic leukemia (MP-CMML) in humans, and both ar

185 ures and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those

186 ease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70

187 and SRSF2 mutations are frequent in chronic myelomonocytic leukemia and advanced forms of MDS.

188 tions are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as d

189 e-1 (FIP1L1)-PDGFRalpha, which cause chronic myelomonocytic leukemia and hypereosinophilic syndrome,

190 tantly, Bcl11a is expressed in human chronic myelomonocytic leukemia and juvenile myelomonocytic leuk

191 closely related neoplasms (including chronic myelomonocytic leukemia and MDS-myeloproliferative neopl

192 We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with system

193 uting to the pathogenesis of NS and juvenile myelomonocytic leukemia caused by PTPN11 gain-of-functio

194 MLL-AF6 leukemias as well as in ML2, a human myelomonocytic leukemia cell line bearing the t(6;11)(q2

195 lcytosine (ara-C)-induced apoptosis in human myelomonocytic leukemia cells (U937).

196 Simultaneous exposure (24 h) of U937 myelomonocytic leukemia cells to 100 nM flavopiridol and

197 detection of shared origin of LCH and acute myelomonocytic leukemia driven by TET2-mutant CD34(+) ce

198 zation and shares some features with chronic myelomonocytic leukemia in adults.

199 Juvenile myelomonocytic leukemia is an aggressive and frequently

200 Juvenile myelomonocytic leukemia is an aggressive myeloproliferat

201 In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that

202 BCOR is also mutated in chronic myelomonocytic leukemia patients (7.4%) and BCORL1 in AM

203 n 161 of 1458 patients (11%); 26% of chronic myelomonocytic leukemia patients harbored 7q uniparental

204 Juvenile myelomonocytic leukemia patients without PTPN11 mutation

205 Decitabine's mechanism of action in chronic myelomonocytic leukemia remains incompletely understood.

206 chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia samples.

207 lomonocytic origin, and a diagnosis of acute myelomonocytic leukemia was rendered.

208 Patients with chronic myelomonocytic leukemia were first screened for JAK2 and

209 actory acute myelogenous leukemia or chronic myelomonocytic leukemia were treated with 10.36 to 37.0

210 mia [RA]/RA with ringed sideroblasts/chronic myelomonocytic leukemia with < 5% bone marrow blasts, 63

211 ronic myeloproliferative syndrome or chronic myelomonocytic leukemia with eosinophilia.

212 acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.

213 MDS/MPN overlap syndrome (including chronic myelomonocytic leukemia).

214 ferative neoplasm (SM-MPN), 36 (29%) chronic myelomonocytic leukemia, 28 (23%) myelodysplastic syndro

215 clinical and molecular features with chronic myelomonocytic leukemia, a similar disease in adults.

216 liferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International

217 Juvenile myelomonocytic leukemia, acute myeloid leukemia (AML), a

218 n specific human cancers, including juvenile myelomonocytic leukemia, an aggressive myeloproliferativ

219 tic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with

220 h myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leuk

221 roblasts, TET2/SRSF2 comutation with chronic myelomonocytic leukemia, and activating CSF3R mutation w

222 All subtypes of myelodysplasia, chronic myelomonocytic leukemia, and acute myeloid leukemia with

223 re common in acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome.

224 ted with marked thrombocytosis, and juvenile myelomonocytic leukemia, are clonal hematologic diseases

225 tive neoplasms (MDS/MPNs), including chronic myelomonocytic leukemia, atypical chronic myeloid leukem

226 ectively analyzed 110 patients with juvenile myelomonocytic leukemia, given single-unit, unrelated do

227 Chronic myelomonocytic leukemia, isolated 5q- syndrome, unclassi

228 ons occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrome, B-cell

229 s SM-MPN, systemic mastocytosis with chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytos

230 ed in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hyper

231 antation model efficiently induces a chronic myelomonocytic leukemia- or acute myeloid leukemia-like

232 ents suffering from MDS (n = 52) and chronic myelomonocytic leukemia-1 (n = 2).

233 elevant proportion of children with juvenile myelomonocytic leukemia.

234 yelodysplastic syndromes (MDSs), and chronic myelomonocytic leukemia.

235 d SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia.

236 A 3-year-old boy was treated for juvenile myelomonocytic leukemia.

237 econdary acute myeloid leukemia, and chronic myelomonocytic leukemia.

238 , genomic instability, and aggressive, fatal myelomonocytic leukemia.

239 s, myeloproliferative neoplasms, and chronic myelomonocytic leukemia.

240 bling the myeloproliferative form of chronic myelomonocytic leukemia.

241 n found in a subset of patients with chronic myelomonocytic leukemia.

242 ice that closely models juvenile and chronic myelomonocytic leukemia.

243 eloproliferative disorder resembling chronic myelomonocytic leukemia.

244 loid metaplasia, and, less commonly, chronic myelomonocytic leukemia.

245 es, including an increased risk for juvenile myelomonocytic leukemia.

246 viously described BTs with transformation to myelomonocytic leukemia.

247 ws efficacy in a nude mouse model of chronic myelomonocytic leukemia.

248 duct of the t(5;12) translocation in chronic myelomonocytic leukemia.

249 ight loss as initial manifestations of acute myelomonocytic leukemia.

250 ents with acute myeloid leukemia and chronic myelomonocytic leukemia.

251 tosis, including but not limited to, chronic myelomonocytic leukemia.

252 No patient with JXG developed chronic myelomonocytic leukemia.

253 ren with CBL syndrome and transient juvenile myelomonocytic leukemia.

254 sented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/

255 nduced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/myeloproliferati

256 true NK-cell tumors (n = 18), de novo acute myelomonocytic leukemias (1 of 14, 7%), or mature T-cell

257 uch as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced b

258 derived colonies in 28 patients with chronic myelomonocytic leukemias (CMML), the most frequent MPN/M

259 g and is inactivated in a subset of juvenile myelomonocytic leukemias (JMMLs).

260 ptor (TEL-PDGFbetaR) is expressed in chronic myelomonocytic leukemias associated with t(5;12)(q33;p13

261 Myelomonocytic leukemic cells from primary or transplant

262 ave shown that MCK-2-enhanced recruitment of myelomonocytic leukocytes with an immature phenotype occ

263 rin CD11b is a differentiation marker of the myelomonocytic lineage and an important mediator of infl

264 is an autoinflammatory syndrome in which the myelomonocytic lineage appears to play a pivotal role.

265 Potential immunomodulatory receptors on myelomonocytic lineage cells that bind extracellular Hsp

266 pressed by monocytes, macrophages, and other myelomonocytic lineage cells.

267 lves with sialic acids, which can engage the myelomonocytic lineage inhibitory receptor Siglec-9, the

268 HPCs impaired their differentiation into the myelomonocytic lineage, it potently promoted hemoglobin

269 s in mature lysozyme-expressing cells of the myelomonocytic lineage.

270 ne marrow cells skews differentiation toward myelomonocytic lineage.

271 They develop from hematopoietic cells of the myelomonocytic lineage.

272 identified the presence of B cells, several myelomonocytic lineages, fibroblast and epithelial cell

273 as early (pu.1) and late (mpo and l-plastin) myelomonocytic lineages.

274 uce macrophage morphology or upregulation of myelomonocytic markers in U937 cells, suggesting that th

275 lex because upregulation of some but not all myelomonocytic markers required endogenous PU.1.

276 sibility and expression of genes involved in myelomonocytic maturation and differentiation.

277 Long-term cultures displayed a myelomonocytic morphology while retaining multilineage p

278 c-KIT and provide the first animal model of myelomonocytic neoplasia initiated by human KIT(D816V).

279 sults confirmed that the infiltrate was of a myelomonocytic origin, and a diagnosis of acute myelomon

280 blastoid, lymphoid-appearing, and subsequent myelomonocytic phases of this disease.

281 retrovirus-induced myeloid leukemias of the myelomonocytic phenotype were found to have hypermethyla

282 is a hematopoietic stem cell derivative, the myelomonocytic precursor (MMC).

283 vitro, HOXB6 immortalized a factor-dependent myelomonocytic precursor capable of granulocytic and mon

284 riving PD-L1 overexpression in both immature myelomonocytic precursors and committed CD206(+) macroph

285 only fractions containing c-kit(+) immature myelomonocytic precursors are capable of contributing to

286 for PU.1 has been shown to cause a shift in myelomonocytic progenitor fate toward the myeloid lineag

287 hifts in the frequencies of erythroid versus myelomonocytic progenitors following Tet2 or Dnmt3a loss

288 in the pool of hematopoietic cells known as myelomonocytic progenitors.

289 eloid NK precursors are derived from granulo-myelomonocytic progenitors.

290 exclusively to myeloid progenitors and their myelomonocytic progeny.

291 ost response and causes a marked increase in myelomonocytic recruitment with an immature phenotype to

292 previously unidentified impact of inhibitory myelomonocytic Siglecs in cancer biology, with distinct

293 To investigate the function of inhibitory myelomonocytic Siglecs in vivo we studied mouse Siglec-E

294 DNAme changes with specific erythroid versus myelomonocytic skews, we provide evidence in support of

295 ast, inflammatory monocytes, the other major myelomonocytic subset, remain virus negative.

296 lete TFPI-K1 in endothelial (TFPI(Tie2)) and myelomonocytic (TFPI(LysM)) cells resulted in viable and

297 ray of cytokines in stably transfected human myelomonocytic U937 cells in response to other TLR agoni

298 tigated by examining the localization of pro-myelomonocytic U937 cells into synovial tissue transplan

299 endogenous TNFalpha.TNFR complexes in human myelomonocytic U937 cells.

300 lls was improved, with an increased ratio of myelomonocytic verus lymphoid lineages.